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Summary 
This review provides an update on current evidence surrounding epidemiology, 
treatment and prevention of lower respiratory tract infection, with special reference to 
pneumonia and influenza, in care home residents.  The care home sector is growing 
and provides a unique ecological niche for infections, housing frail older people with 
multiple comorbidities and frequent contact with healthcare services.  There are 
therefore considerations in the epidemiology and management of these conditions 
which are specific to care homes.  Opportunities for prevention, in the form of 
vaccination strategies and improving oral hygiene, may reduce the burden of these 
diseases in the future.  Work is needed to research these infections specifically in 
the care home setting and this article highlights current gaps in our knowledge. 
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Introduction 
 
In most developed countries, 4 to 8% of people over the age of 65 years live in care 
homes (1), of whom 70 to 90% have some form of activity limitation (2-5).   Around 
40% of United Kingdom (UK) and United States (US) care home residents are 
completely bed bound (4, 6). Care homes vary in size, structure and purpose from 
country to country depending on the wider socio-political context in which they have 
developed, however they globally serve a frail population.  In the UK, the term “care 
home” comprises residential and nursing homes. 
 
Care home residents are susceptible to respiratory tract infections, with a prevalence 
of 0.5 to 4.4 per 1,000 resident days (7).  Pneumonia, in particular, is important as 
the leading infective cause of death amongst care home residents, with mortality 
rates between 6% and 23% (8).  In North America in 1993, assuming a prevalence of 
1 per 1000 resident days, the direct hospital costs relating to an admission for 
pneumonia in a nursing home resident were estimated at $14,000, which would 
exceed $8 billion across 1.5 million nursing home residents (9). 
 
There are specific considerations in the classification, epidemiology, diagnosis, 
management and prophylaxis of both pneumonia and influenza in the care home 
population that makes them worthy of special consideration.  These will be 
considered in turn below.      
Search strategy 
We searched Medline 1950 – December week 4 2009 using the terms [“nursing 
home acquired pneumonia” OR (Pneumonia AND Cross-infection AND Nursing 
homes) OR (Nursing home AND Influenza)].  Results were limited to English 
language articles; reviews other than systematic reviews were excluded. Sixty- four 
relevant articles were identified, of which 21 were duplicates and 43 were included in 
this review.  Relevant papers already known to the authors but not identified using 
the above search strategy were also included. 
 
The terminology of infection in care homes is different 
 
Pneumonia refers to infections of the lung parenchyma that produce visible infiltrates 
on chest radiography, often associated with cough, fever, breathlessness and 
malaise.  If there are no visible changes on the chest radiograph then the illness is 
called a lower respiratory tract infection (LRTI).  It has been proposed that nursing 
home acquired pneumonia (NHAP) be considered separately from community 
acquired pneumonia (CAP) due to the likelihood that the causative organisms, and 
therefore the choice of antibiotic, will differ (10).   
 
Most of the evidence surrounding NHAP comes from US studies and it is difficult to 
compare the prevalence of NHAP in US and non-US populations because of 
international variation in care homes and the medical therapies to which residents 
are exposed.  For example, in the US, nursing home residents with severe 
pneumonia may be intubated and ventilated(11)(12) - which may both facilitate and 
cause higher diagnosis of drug-resistant pathogens. Such practice would be rare in 
the UK. 
 
Healthcare associated pneumonia (HCAP) is a relatively new term which includes 
patients in nursing homes as being at higher risk of having pneumonia caused by 
multi-resistant organisms (13).  Taking the UK as an example, a study conducted in 
2001 compared the organisms causing community acquired pneumonia in nursing 
home residents with age and dependency matched controls living in their own home, 
demonstrating little difference between the two.(14)  It is therefore unclear whether 
NCAP or HCAP are useful classifications in the UK.  
 
The terminology surrounding influenza in care homes is the same as in the general 
population, but is described here to clarify discussion about influenza subtypes later 
in the article.  Influenza refers to the infections caused by the influenza virus, of 
which there are three types, A, B and C, classified according to viral matrix- and 
nucleo-proteins.  Of these, only A and B cause significant infection in humans.  
Influenza viruses are described according to their surface antigens, haemaglutinin 
and neuraminidase, which are glycoproteins known to play key roles in the 
replication cycle of the virus.  Influenza A expresses 16 subtypes of haemaglutinin 
(H1-H16) and 9 subtypes of neuraminidase (N1 –N9), whilst influenza B expresses 
only one type of each antigen.   
 
The epidemiology of pneumonia and influenza in care homes is different from 
in the general population 
 
Care homes are unique ecological niches for infection because their residents have 
reduced function, have numerous comorbidities, and have higher rates of dementia.  
They live in communities in which they are grouped with other patients of similar age 
and vulnerability.  A consequence of this is that the epidemiology of pneumonia and 
influenza in care homes, particularly in terms of outbreak management and infection 
control, is different from that in both the acute hospital and community sectors.   
 
In general, mortality from pneumonia in care home residents is high (12-21%) (15-
18), and residents are more likely to die of pneumonia than other healthcare 
associated infections (19).  The higher mortality in residents is explained to a large 
extent by their pre-morbid status, with mortality rates attenuated compared to 
community controls when weight loss, dementia, aspiration risk and functional status 
are considered (14, 20).  
 
Bacterial pneumonia is not generally regarded as contagious and isolation measures 
are therefore not routinely recommended.  However, occasional outbreaks have 
been reported in care homes (21, 22), presumably because of the close proximity in 
which residents live.  Where reported, outbreaks have been associated with low 
pneumococcal vaccination rates, making a compelling case for vaccination in this 
cohort, despite concerns about vaccine efficacy (see below). 
 
By contrast, influenza is characterised by epidemics.  Influenza surface antigens 
frequently undergo structural modification, leading to a period when populations 
become vulnerable to infection whilst population immunity catches up.  Subtle 
modification from season to season, usually caused by point mutation in the genetic 
code for the surface glycoproteins, is known as antigenic drift and is the driving 
factor behind seasonal influenza outbreaks.  Rarely, entirely novel H or N antigens 
emerge, often as a consequence of genetic reassortment with swine or avian 
influenza viruses.  This is known as antigenic shift and results in a strain to which 
there is limited or no population immunity, which often results in pandemic influenza.   
The concept of an “influenza season” comes from temperate latitudes in the northern 
and southern hemisphere, where characteristic peaks of influenza are recorded in 
the autumn and winter months.  Care home outbreaks mirror the prevalence in the 
wider population and therefore tend also to be seasonal at these latitudes.  In 
tropical climates, influenza is more common during the wet season but seasonal 
differences are less pronounced (23). 
 
Once introduced into a care home, influenza can spread rapidly because of close 
contact among residents, their poor overall health status and the challenges of 
infection control in care homes.   Rates of pneumonic conversion from influenza can 
be as high as 42% during outbreaks (24).  During the influenza season, case-fatality 
rates for care home residents regularly exceed 5% and have been reported to 
exceed 70% during outbreaks (25-28).  As with pneumonia, the risk of mortality or 
significant morbidity from influenza increases with age and co-morbidities (29)  
 
Spread of influenza is likely to occur via close personal contact, and in particular 
through contact with oral secretions (30).  Staff represent a potential vector for 
spread through their role in mouth care and feeding.  Recommended measures to 
minimise spread during an outbreak include regular handwashing for staff, ready 
availability of portable alcohol gel for hand cleansing and, where staff have 
prolonged close contact with residents, the use of face-masks, gloves and aprons 
(31-33).  However the evidence for effectiveness of infection control in the care 
home setting is limited (34). This is possibly due to the fact that hospital-style 
measures are made difficult by the need to provide a homely setting and allow 
freedom of movement.  Lack of dedicated infection control staff and low staff to 
resident ratios also contribute.   
 
Oropharyngeal commensals are different in the care home population 
 
Lower respiratory tract infections result from the combination of a potential pathogen 
adhering to the oro- or nasopharynx, the provision of an easy path to the lower 
respiratory tract (e.g. tendency to aspirate), and an immune system unable to 
eradicate the pathogen either at the oro- or nasopharynx or in the lungs.  Age, 
number of comorbidities (35-37), malnutrition (38) and frailty influence the latter.   
 
Micro-aspiration, where small amounts of oral-pharyngeal secretions are aspirated 
into the lungs, is likely to be an aetiological factor in most pneumonias and explains 
how differences in oral-pharyngeal colonisation lead to differences in the spectrum of 
organisms causing pneumonia in different populations (39) (7, 40).    
 
Oral colonisation with pathogens known to cause pneumonia (e.g. P. aeruginosa, S. 
aureus ) occurs more commonly in hospitalised and institutionalised people (39) (7, 
40).  These bacteria are also encountered very commonly in those with nasogastric 
tubes in- situ (41, 42).  In addition, both community and hospital acquired pneumonia 
have been associated with proton pump inhibitor prescription (43, 44) suggesting 
possible gastric bacterial overgrowth as an explanation for the presence of these 
bacteria.   
 
In addition to guiding antibiotic prescribing for pneumonia in care home residents, 
these data suggest a possible role for manipulating the organisms that colonise the 
oropharyngeal tract as a way of modifying pneumonia risk in care home residents. 
 
Diagnosing pneumonia or influenza in care home residents is more difficult 
than in the general population 
 
Typical symptoms of lower respiratory tract infection (LRTI) include cough, fever, 
breathlessness, malaise, myalgia, and pleuritic pain.  Viral infections may also cause 
upper respiratory tract symptoms such as sore throat and sneezing.  As with many 
older patients, the clinical presentation of pneumonia in care home residents is often 
non-specific because of general frailty, symptoms of comorbid illness, impaired 
communication and/or cognition, and altered response to sepsis (34). Fever, 
productive cough and pleuritic chest pain are less common in older people, whilst 
non-specific presentations such as falls, delirium, anorexia, or generalised weakness 
are common (14, 45). 
 
The only English-language guideline for diagnosing pneumonia in care home 
residents comes from the US and is based upon consensus by a multi-specialty 
consensus panel (46).  It suggests that a diagnosis of probable pneumonia can be 
made based on two of the following factors being present: new or worsening cough, 
new purulent sputum, fever >100ºF, or over 2ºF above normal, or <96ºF, dyspnoea, 
respiratory rate >25, tachycardia, new or worsening hypoxia, pleuritic chest pain, 
decline in cognition or functional status, or new crepitations or wheezes heard on 
auscultation.  Unlike other pneumonia guidelines, a chest radiograph is not required 
for diagnosis.  The rationale for this is not made clear but, possibly, is a pragmatic 
decision based on the limited access to radiography in the care home setting and the 
possible deleterious effects of moving to an acute care setting to obtain an x-ray. 
 
The presence of such symptoms is not, however, a reliable indicator of pneumonia, 
as opposed to other lower respiratory tract infections, nor does it give any indication 
as to the causative organism(24).  Hui et al (47) found the aetiological agent in such 
presentations amongst care home residents to be bacterial in 53.3% of the cases 
where a pathogen was identified.  Influenza virus type A or B caused 7.4% of cases.  
RSV, metapneumovirus and parainfluenza were all more prevalent than influenza.    
 It is difficult to grade severity of pneumonia in older patients, including care home 
residents.  The CURB-65 criteria (widely used in community acquired pneumonia) 
have a high negative predictive value (95.9%) and sensitivity (85.2%) but a low 
specificity (57%) and positive predictive value (24.5%) in community-dwelling older 
patients (48).  This makes it easy to decide who has non-severe pneumonia but 
much more difficult to establish with certainty who has severe pneumonia and 
therefore requires hospitalisation  – strict adherence to the CURB criteria will result 
in a significant number of unnecessary hospitalisations, particularly as high-quality 
care can often be provided within the care home setting. 
 
Given the low sensitivity and specificity of clinical diagnosis (i.e. those with 
pneumonia at autopsy not displaying clinical symptoms or signs, and other 
respiratory illnesses being classified as pneumonia), a gold-standard investigation 
for pneumonia would be useful.  Unfortunately, no such test is available. Inter-rater 
agreement between radiologists interpreting chest radiographs of nursing home 
residents is described as “fair” (49) and computed tomography does not reliably 
establish the diagnosis (50).   
 
Influenza is diagnosed by clinical symptoms during epidemic or pandemic situations 
and by laboratory testing during outbreaks.  Real-time polymerase chain reaction 
(PCR) analysis of nose and throat swabs in viral transport media allows same-day 
diagnosis to aid in infection control during outbreaks, although this is dependent on 
primary care physicians both making the provisional diagnosis and requesting the 
investigation. 
 
Mouth care may have a specific role in prophylaxis of LRTIs in care homes 
 
Given that the pathogenesis of NHAP appears to be microaspiration of infected oral 
secretions, it is possible that improving oral hygiene may reduce rates of pneumonia.  
Two systematic reviews have been undertaken considering oral hygiene and 
pneumonia.  Scannapieco et al reviewed 21 studies and concluded that further 
research was needed but that evidence pointed to a link between the two (51).  
Azparnooh et al suggested a significant effect from oral hygiene, but included papers 
from a wider group of patients (e.g. intensive care and nursing home) and 
considered a wider range of diseases (52).  Randomized controlled trials in this area 
are necessary. 
 
One study considered in the reviews above is worth highlighting. Yoneyama et al 
(53) (17) randomised 418 nursing home residents to receive oral hygiene (manual 
toothbrushing plus povidone iodine oral scrubs) or no intervention, with the outcome 
measure being radiologically-confirmed pneumonia.  34 of 182 participants 
developed pneumonia in the no oral care group, compared to 21 of 184 in the oral 
care group OR 1.67 (CI 1.01-2.75, p=0.04).  This study is the only intervention study 
in non-ventilated persons that is adequately powered and has not yet been repeated. 
 
Bassim et al subsequently undertook an intervention trial where one ward of patients 
was assigned an oral care practitioner and another ward was not (54).  The 
intervention group had a similar rate of pneumonia at the end of the study but it was 
noted that this group would have been expected to have a higher rate given their 
higher prevalence of comorbidities.  When adjusted for risk factors such as age, 
functional status, cognitive impairment and clinical suspicion of aspiration 
pneumonia, the odds ratio for death in the no oral care group was 3.57 (p=0.3).   
 
There is no evidence that feeding strategies modify pneumonia risk 
 
Given that both aspiration and malnutrition represent risk factors for developing 
LRTIs and that both are common in the care home population, it seems logical to 
consider improving feeding strategies as a preventative intervention.  Loeb et al 
conducted a systematic review of feeding interventions to prevent aspiration 
pneumonia in 2003 and retrieved 8 randomised controlled trials evaluating 
positioning changes, dietary interventions, pharmacologic therapies, oral hygiene, 
and tube feeding (55).  None of the studies retrieved showed positive results, 
however most were statistically underpowered.  Further work in this area has been 
suggested. 
 
Vaccination against pneumonia and influenza in care home residents is less 
effective than in the general population 
 
Streptococcus pneumoniae remains an important cause of NHAP and in the only 
organism with an available vaccine for older people.  The World Health Organisation 
recommends that all adults over the age of 65 be vaccinated with the 23-valent 
Pneumococcal vaccine (PPV23).  While the body of evidence available suggests a 
protective effect from the vaccine against invasive pneumococcal disease (56) (that 
is pneumococci detected from any site); the vaccine is less effective in older than 
younger people (57) and immunity wanes over time (58). 
 
When endpoints such as hospitalisation for pneumonia are considered rather than 
invasive pneumococcal disease, the vaccine appears to be ineffective in older 
people (59).  Huss et al recently re-analysed vaccine trials, and found that the 
vaccine conferred little protection once trials with inadequate blinding were excluded 
(60, 61).   As stated earlier, the PPV23 vaccination may confer some herd immunity, 
reducing the likelihood of pneumococcal outbreaks in care homes, however the 
evidence for this is based around case reports.  The risk-benefit ratio of 
pneumococcal vaccination in frail older people therefore remains uncertain and 
guidelines may be subject to revision in the future. 
 
Similarly, most developed and many developing countries now recommend routine 
vaccination of older citizens against influenza (62).  Whilst such guidelines 
necessarily include the care home population, the World Health Organisation 
guideline identifies care home residents as being at particularly high risk, and 
therefore representing a priority for influenza vaccination (63).   
 Current recommendations are based on randomised controlled trials demonstrating 
efficacy of influenza vaccination which were conducted in young, healthy, ambulatory 
populations (64).  No such work has been undertaken in the care home population 
and would now be considered unethical in the face of overwhelming expert 
consensus that vaccination should take place.  Observational cohort studies, 
however, suggest that influenza vaccination in this group is effective and reduces the 
incidence of respiratory infection by 33-42% and the risk of pneumonia by 43% (65, 
66), this is compared with a reduction in the incidence of influenza of 78% in young 
fit subjects.  Older patients are less responsive to vaccination(67),  probably because 
of immunosenescence (68), and lower rates of seroconversion and seroprotection 
are seen following influenza vaccination in the elderly population compared with 
younger controls (69).  However, despite its lower efficacy, observational studies 
suggest that homes with high uptake of influenza vaccination demonstrate a lower 
incidence of influenza-like illness (26, 65), again suggesting a possible role for herd 
immunity. 
 
Vaccination of staff against influenza is important in care homes 
 
Two large cluster-randomised controlled trials, and a Cochrane review drawn from 
them, have demonstrated that immunisation of staff has no effect upon incidence of 
influenza in care home residents but does reduce mortality, largely by reducing the 
incidence of complications (25, 70, 71).  This effect is only seen when residents are 
also immunised.  No such data exists for staff vaccination against pneumococcus. 
 Despite the demonstrated efficacy of staff vaccination, uptake rates for flu vaccines 
amongst health care workers are historically low. Only 16.5% of health care workers 
in England, for example, accepted vaccination in the 2008-2009 influenza season 
despite the vaccine being freely available and uptake being encouraged by 
employers (72).  Immunisation rates in Dutch care home workers have been 
reported at 11% despite national guidelines recommending universal immunisation 
for staff (73).  
 
Targeted interventions, including education programmes, financial incentives and 
reverse consent - where workers have to sign a consent form to demonstrate that 
they understand the risks taken by refusing vaccination – can improve vaccine 
uptake rates (74, 75).  However, such practices are not widespread.  Mandatory 
vaccination of care home workers, where employment is conditional upon 
vaccination status, has been suggested as a possible solution (76).  The ethical 
challenges of such a policy are clear – balancing the need to protect patients from 
infection against the loss of autonomy for staff and the small possibility that they may 
suffer harmful side effects as a consequence of vaccination – and thus it remains the 
subject of debate rather than policy (76, 77). 
 
The evidence-base and guidelines for chemoprophylaxis in care homes are 
different from the wider population   
 
Given the above comments about oral hygiene and feeding interventions, it is useful 
to consider pharmacological interventions to prevent aspiration pneumonia.  El Solh 
et al conducted a systematic review of these in 2007, considering angiotensin 
converting enzyme inhibitors, capsaicin, amantadine, cabergoline, theophylline and 
cilostazol (11).  The latter four drugs could not be recommended due to adverse 
effects, and there was insufficient evidence to recommend the former two.  The 
review concluded that further large scale randomised controlled trials were needed.  
 
An earlier systematic review by Loeb et al (55) considered use of the drugs cilostazol 
and amantadine, and found that both lowered pneumonia incidence at 3 year follow-
up, however state that both have a high incidence of undesirable side effects that 
limit their widespread use.   
 
Neuraminidase inhibitors may be used to prevent influenza infection in exposed 
people.  Indeed, the evidence for chemoprophylaxis is more convincing than that for 
treatment in care home residents.  A randomized placebo-controlled trial of 
oseltamivir in 548 nursing home residents whose co-residents had laboratory-
confirmed influenza demonstrated reduced incidence of pneumonia, antibiotic 
prescribing and case mortality at 8 week follow-up(78).  A similar randomized 
placebo-controlled trial of zanamivir in 494 residents demonstrated no effect on the 
incidence of laboratory confirmed influenza but a statistically significant 70% 
reduction in the incidence of influenza associated with pyrexial symptoms – possibly 
a clinically significant finding. (79) 
 The UK National Institute for Clinical Effectiveness (NICE) recommends use of 
oseltamivir and zanamivir for post-exposure prophylaxis in at-risk people living in 
long-term residential or nursing homes, whether or not they are vaccinated (80).  
Similar guidance on prophylaxis has been issued by the US Centre for Disease 
Control and Prevention (CDC) (81). 
 
Oseltamivir resistant strains of influenza have recently been detected in both the 
USA and Europe.  Currently, this resistance is limited only to H1N1 strains (82).  No 
zanamivir-resistant strains have been identified and it is postulated that the 
molecular structure of zanamavir means that it is fundamentally less likely to 
engender resistance.  Oseltamivir is taken orally, whilst zanamivir is administered by 
inhalation using a diskhaler device.  The inhalation route means that zanamavir is 
not recommended for use in patients with underlying lung disease, and some older 
patients have been shown to find loading and priming the inhaler difficult (83).  Both 
of these factors limit its usefulness in the care home population. 
 
The choice of antibiotic therapy for pneumonia is more complex in the care 
home population 
 
Intravenous antibiotic therapy does not appear to confer a survival advantage in care 
home residents (20).  Therefore residents can be treated in-situ with oral antibiotic 
therapy and only require admission to hospital where they are unable to take oral 
medications, require oxygen or intravenous fluids – which are not possible in the 
care home setting in many countries.  The primary consideration in treating care 
home pneumonias is matching antibiotic therapy to the organisms prevalent in the 
care home population, as inadequate antibiotic therapy is associated with higher 
mortality(10).  
 
The introduction of widespread antibiotic use has seen the emergence of less 
pathogenic bacteria causing respiratory infections in older people, including 
Staphylococcus aureus, coliform bacteria and Pseudomonas aeruginosa (84-86).  
Residents seem to be at particular risk of drug-resistant pneumonia if they have 
poorer functional status, have received antibiotics within the past 90 days or a recent 
hospital stay (12, 87). 
 
This has led to revised antibiotic guidelines, in the US at least, for care home 
residents.  New guidelines were issued by the American Thoracic Society in 2005 
(88) covering HCAP which have been applied to nursing home residents hospitalised 
with NHAP and have changed recommendations to include antibiotic cover for the 
more unusual pathogens seen in this group.    
 
El Solh et al compared outcomes of 334 nursing home residents hospitalised with 
NHAP/HCAP, of which 76 were treated using the new 2005 guideline and 258 were 
treated using the 2003 guideline, which did not include cover for MRSA or 
Pseudomonas aeruginosa (16).  Despite the rationality of this approach, there was 
no difference in the time to clinical stability, in-hospital or 30-day mortality.  This, 
combined with the uncertainty over whether pathogens in other countries mirror 
those seen in US nursing homes, means that standard CAP antibiotic protocols are 
used as first-line treatment for care home residents in many regions, with more 
broad-spectrum therapies used only if patients fail to respond to treatment.   
 
The guidelines for treating influenza in the care home population are different 
– although the evidence base for this is uncertain 
 
In treating patients with proven influenza, neuraminidase inhibitors have been shown 
to reduce the number of days until alleviation of symptoms, return to normal activity 
or resolution of fever.  However, no specific treatment trials have been undertaken in 
the care home population and, where high-risk and elderly populations have been 
studied, the treatment effect, although present, has failed to achieve statistical 
significance(89).  The elderly cohorts in these studies were small and, as a 
consequence, they were inadequately powered to measure complications as an 
outcome. 
 
Despite the uncertainty about treatment effect, the UK National Institute of Clinical 
Excellence (NICE) regards the care home population as high-risk with respect to 
influenza and suggests that, when the virus is known to be circulating, treatment with 
oseltamivir should be commenced for residents with flu-like illness.  Treatment is 
also supported for influenza-like illness in care home residents outside of influenza 
season but only when virological confirmation that influenza is the aetiological agent 
has been made (90).   
 
These guidelines are not replicated elsewhere in the world and recent concern has 
focused on possible inconsistencies in the pharmaceutical research undertaken to 
evaluate oseltamivir, upon which NICE have based their recommendations (91).  It is 
therefore possible, particularly given the paucity of care home specific data, that 
these guidelines will be subject to review in the future. 
 
Oseltamivir has recently been the subject of much attention as a consequence of its 
heavy utilization for treatment of infected individuals in some regions during the 
current Swine-Origin Influenza A Virus (S-OIV) pandemic. The requirements for 
commencement in the context of a pandemic vary from country to country, as does 
the requirement for virological confirmation of infection by throat swab prior to 
commencement.  In most cases, however, the elderly population, incorporating care 
home residents, are identified as a high risk group, where treatment can be 
commenced even in the absence of a pyrexia (92, 93).  
 
The threat posed by pandemic influenza is different in care homes than in the 
wider population 
 
A novel H1N1 Swine-origin influenza A virus (S-OIV) emerged in California and 
Mexico in April 2009(94) and has since spread around the world.  The World Health 
Organisation (WHO) has defined this as a pandemic based upon its criterion of 
sustained human-to-human spread over multiple geographical regions(95). 
 
At a population level, care home residents are potentially at lower risk from this virus 
than would conventionally be the case during a pandemic.  Under 60s make up the 
majority of serologically confirmed cases of influenza, with evidence that up to 33% 
of over 60s carry antibodies which are protective against S-OIV(96).   This is likely to 
be a consequence of close similarities between the antigen profile of S-OIV and the 
strains of human H1N1 in prevalent circulation before the 1950s(97).  At an 
individual level, however, care home residents remain at increased risk of secondary 
complications if they contract the virus because of their frailty and comorbidities.  
    
Pandemic influenza will challenge care homes both as care providers and as 
organisations.  Contingencies will be required to deal with increased care 
requirements amongst residents, for isolation of infected residents and to cover 
periods of staff absence(98).  If homes are closed to new admissions during a 
pandemic, as is routine practice during normal influenza outbreaks, this will lead to 
loss of financial income, which will be compounded if the mortality rate is high.  The 
importance of these issues varies from country to country, depending on the 
economic model underpinning the care home sector.  In the UK, for example, care 
homes are predominantly run as small private companies which are particularly 
vulnerable to the economic pressures of a flu pandemic (98).  In the USA, by 
contrast, nursing homes might be called on to deliver first-care if acute hospital 
facilities become overwhelmed, providing an additional stressor during a difficult time 
but also representing a possible revenue stream (99).  There is evidence, however, 
that the care home sector in both countries has been engaged poorly in pandemic flu 
planning and, as a consequence, is potentially underprepared (98, 99). 
 
Immunisation practices for care home residents during a pandemic will vary 
depending upon national policies.  In the UK, for example, over 65s in high-risk 
groups, including the care home population, will be vaccinated as part of the first 
wave of vaccination(33).  In the USA, by contrast, this group are not listed as high 
priority – with attention focusing instead on younger patients with co-
morbidities(100).  
 
Conclusions 
 
Both influenza and pneumonia cause considerable morbidity and mortality in care 
home residents.  The care home population is different from the population at large 
in terms of age, co-morbidity, functional status and the communal environment in 
which they live.  These differences result in differences in the behaviour of 
pneumonia and influenza, and how they are treated. 
 
A number of issues remain unclear.  It is not certain that differences between HCAP 
and CAP identified in US nursing home residents are apparent in care home settings 
in other countries.  Nor is it clear that modifying antibiotic prescribing in US patients 
to allow for the differing spectrum of infection in HCAP makes any difference to 
clinical outcomes.  Therefore the usefulness of this distinction remains uncertain. 
 There is doubt that current diagnostic guidelines allow diagnosis of pneumonia in 
care home resident with any degree of specificity.  Further work to identify reliable 
markers of pneumonic infection in this cohort would be welcome. 
 
It is clear that aspiration of oropharyngeal commensals has some role, particularly, in 
the aetiology of nursing home acquired pneumonia and it is possible that this allows 
for improved oral care as a therapeutic intervention. Adequately powered 
randomized-controlled trial data in this area is very much needed. 
 
Vaccination for influenza is indicated for both nursing home staff and residents, and 
is synergistic.  There is no evidence-base to suggest that pneumococcal vaccination 
affects individual clinical outcomes in this cohort, although case reports suggest that 
it may convey protective herd immunity at a whole home level.  Guidelines do not 
currently reflect this uncertainty. 
 
Neuraminidase inhibitors are rapidly growing to become controversial therapies.  
Their use in prophylaxis in care homes is supported by independent randomized-
controlled trials. However their role in treatment is less clear and guidelines may 
have to be reviewed to reconsider recent revelations about the quality of clinical 
evidence supporting the use of neuraminidase inhibitors in this respect. 
 
Pandemic influenza will challenge both the clinical and managerial skills of the care 
home sector.  A pandemic will test the financial models of care homes at a time in 
which they are already facing considerable financial constraints.  There is evidence 
that current planning may be insufficient and it is likely that further efforts are 
required to ensure preparedness. 
 
Considerable effort is required, therefore, to establish an evidence-base for 
management of these infections in care homes.  Whilst international guidelines and 
cross-national research may prove useful in this respect, the differences between 
care homes from country to country mean that one set of solutions may not suit all.  
The care home population is different from the population at large in a variety of 
ways with respect to pneumonia and influenza.  We must understand these 
differences more thoroughly if we are to provide gold standard care to these patients. 
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